News & Updates

Postoperative salvage radiotherapy (SRT) plus 6 months of androgen deprivation therapy (ADT) with abiraterone acetate/prednisone (AAP) and apalutamide (Apa) results in better progression-free (PFS) and metastasis-free survival (MFS) among patients with prostate cancer, findings from FORMULA-509 have shown. However, the primary analysis did not reach the prespecified threshold for statistical significance.

Treatment with stereotactic body radiation therapy (SBRT) followed by sorafenib results in better overall (OS) and progression-free survival (PFS), with no increase in adverse events (AEs), compared with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC), as shown in a phase III study presented at the 2023 ASCO GI Cancers Symposium.

Treatment with the combination of gefitinib and chemotherapy appears to yield significant increases in progression-free survival (PFS), intracranial PFS, and overall survival in patients with untreated EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases as compared gefitinib monotherapy, according to the results of the phase III GAP BRAIN study.

Several patients with nonsmall cell lung cancer (NSCLC) treated with nivolumab report developing immune-related adverse events (irAEs), primarily affecting the skin, lungs, and gastrointestinal system, according to a study.

A combination of trifluridine/tipiracil (FTD/TPI) and bevacizumab provided significant survival benefit when used as third-line treatment for refractory metastatic colorectal cancer (CRC) than FTD/TPI alone, findings from the phase III SUNLIGHT study suggest.

Lung cancer screening based on a risk model is more cost-effective than the 2021 recommendation by the US Preventive Services Task Force (USPSTF), meriting further consideration for the former, reports a recent study.